UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 25, 2015

PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware
1-3619
13-5315170
(State or other Jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

235 East 42nd Street
New York, New York
(Address of principal executive offices)

  
10017
(Zip Code)

Registrant's telephone number, including area code:

(212) 733-2323

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[   ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 25, 2015, the Company’s Board of Directors elected Joseph J. Echevarria (former Chief Executive Officer of Deloitte LLP) to serve as a member of the Board, effective immediately. In addition, he was elected to the Audit Committee, the Regulatory and Compliance Committee, and the Science and Technology Committee of the Board.

Mr. Echevarria has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors.

In connection with Mr. Echevarria’s appointment, the Company reports the following related party transactions under Item 404(a) of Regulation S-K.  In 2014, in the ordinary course of business, the Company engaged Deloitte LLP with respect to, among other things, financial due diligence, merger and acquisition support, marketing and sales strategy support, project management and compliance support.  For the year ended December 31, 2014, the total fees paid to Deloitte for these matters were less than 0.3% of Deloitte’s revenues for its fiscal year ended May 31, 2014.

The press release, dated June 25, 2015, announcing the election of Mr. Echevarria is attached hereto as Exhibit 99. The information contained in the press release is deemed to be filed under the Securities Exchange Act of 1934, and such press release is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.  
(d) Exhibits
    
     
Exhibit No. Description  
99 Press Release dated June 25, 2015  
     

 

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

   
PFIZER INC.
     
   
By: /s/  Margaret M. Madden
Margaret M. Madden
   
Title: Vice President and Corporate Secretary
Dated: June 25, 2015             Chief Governance Counsel

 

 

EXHIBIT INDEX

Number

 Description
99 Press Release dated June 25, 2015

 

EX-99 2 x99625.htm PFIZER INC. PRESS RELEASE DATED JUNE 25, 2015 Pfizer Inc. Press Release

Exhibit 99

 
For immediate release: Media Contact:
June 25, 2015 Joan Campion
  (212) 733-2798
   
  Investor Contact:
  Ryan Crowe
  (212) 733-8160

 

Joseph J. Echevarria Elected To Pfizer's Board Of Directors

NEW YORK, NY – June 25 – Pfizer Inc. today announced the election of Joseph J. Echevarria to its Board of Directors, effective immediately.  Mr. Echevarria also was appointed to the Audit, Regulatory and Compliance and Science and Technology Committees of Pfizer’s Board.

Mr. Echevarria, 58, retired as Chief Executive Officer (CEO) of Deloitte LLP, a global provider of professional services, in August 2014.  He had been with the firm for 36 years and served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner, U.S. Managing Partner and Chief Operating Officer. He was appointed CEO in 2011.

Mr. Echevarria serves as a Director of The Bank of New York Mellon Corporation.  He is a member of the President's Export Council and the Presidential Commission on Election Administration and also serves as Chair of President Obama’s My Brother’s Keeper Alliance. He serves on the Board of Trustees of the University of Miami.

“We are pleased to have Joe Echevarria join Pfizer’s Board of Directors. His expertise in international business and leadership as well as his financial acumen will be an asset to Pfizer’s Board and to the company,” stated Ian Read, Pfizer’s chairman and chief executive officer. “With the addition of Joe to our Board, Pfizer and its shareholders will continue to benefit from a breadth and diversity of experience.”

About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com .

# # # #

 

 

 

 
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pfizer Charts.